PYC Therapeutics Valuation

Is PYCDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PYCDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PYCDA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PYCDA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PYCDA?

Key metric: As PYCDA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PYCDA. This is calculated by dividing PYCDA's market cap by their current revenue.
What is PYCDA's PS Ratio?
PS Ratio	37.9x
Sales	AU$22.06m
Market Cap	AU$835.23m

PYCDA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	34.9x
Enterprise Value/EBITDA	-20.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PYCDA's PS Ratio compare to its peers?

The above table shows the PS ratio for PYCDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	33.4x
CUV Clinuvel Pharmaceuticals	7.7x	21.4%	AU$680.3m
ARX Aroa Biosurgery	3.6x	20.1%	AU$224.2m
IMU Imugene	62.8x	58.2%	AU$312.4m
RAC Race Oncology	59.4x	34.8%	AU$237.8m
PYCDA PYC Therapeutics	37.9x	15.6%	AU$835.2m

Price-To-Sales vs Peers: PYCDA is expensive based on its Price-To-Sales Ratio (37.9x) compared to the peer average (33.4x).

Price to Sales Ratio vs Industry

How does PYCDA's PS Ratio compare vs other companies in the AU Biotechs Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
ARX Aroa Biosurgery	3.6x	20.1%	US$145.57m
IMC Immuron	3.5x	59.7%	US$11.16m
ATH Alterity Therapeutics	4x	25.0%	US$10.36m
BNO Bionomics	2.4x	-5.3%	US$9.52m

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: PYCDA is expensive based on its Price-To-Sales Ratio (37.9x) compared to the Australian Biotechs industry average (9.7x).

Price to Sales Ratio vs Fair Ratio

What is PYCDA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PYCDA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	37.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PYCDA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AVITA Medical

US$326.0m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.79

3.0%

8.9%

AVITA Medical

US$326.0m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.78

3.8%

8.3%

Clinuvel Pharmaceuticals

AU$680.3m

A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

CUV

AU$13.67

-0.1%

-18.0%